Corbus Pharmaceuticals Holdings, Inc.
No enriched coverage for $CRBP in the last 7 days.
Corbus Pharmaceuticals (CRBP) fell 14.36% to $6.92 on Tuesday, extending its losing streak to eight days. The NASDAQ and Dow Jones also declined, down 0.78% and 0.63% respectively.
Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.
Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development
Recent CRBP coverage spans technology, corporate actions and insider activity.
In the last 30 days, CRBP insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($16K). The most active reporter was Ben Yong with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Significant intraday decline suggests short-term bearish pressure.
Positive trial data may boost CRBP stock as investors anticipate Phase 2 and potential market entry.
Positive trial data may boost CRBP share price and attract investor interest in a new obesity drug class.
The trial results suggest strong efficacy and tolerability, likely boosting investor confidence.
The trial results suggest CRBP's obesity drug may become a differentiated oral therapy, likely boosting investor sentiment.
AlphAI scores every news story that mentions CRBP with an AI model for sentiment and relevance, and aggregates insider trades from Corbus Pharmaceuticals Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Corbus Pharmaceuticals (CRBP) fell 14.36% to $6.92 on Tuesday, extending its losing streak to eight days. The NASDAQ and Dow Jones also declined, down 0.78% and 0.63% respectively.
1 min readCorbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.
2 min readCorbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development
2 min readCorbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.
2 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs
2 min readSaxena Nishant C (Chief Business Officer) purchased 2,600 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $9.63 on 2026-08-11.
1 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last
5 min readCorbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 crbp-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “ Agreement ”), dated as of August 03, 2026 (the “ Effective Date ”), is entered into by and between Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) and Leonardo Vi
2 min readSaxena Nishant C (Chief Business Officer) purchased 13,500 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at an average of $7.50 ($7.33–$7.58, $0.10M total) across 2 trades over 2026-06-02 to 2026-06-03.
1 min readCorbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.
4 min read
